TrialsgrambêtaRCTs are beautiful
ESC Congress 2026Présenté ven. 28 août · 12:03 UTC+2Hot Line 1Tous les essais Hot Line →

CMR GUIDE

2026

Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction

In 353 patients with LVEF 36–50 % and scar on cardiac MRI, a primary-prevention ICD did not reduce sudden cardiac death or haemodynamically significant ventricular arrhythmia compared with an implantable loop recorder.

Résultat

Efficacité: Time to composite of sudden cardiac death or haemodynamically significant ventricular arrhythmia (ventricular arrhythmia producing syncope or hypotension, SBP <90 mmHg)HR 0,76 (IC à 95 % 0,37-1,58)

En dessous de 1 en faveur de a primary-prevention ICD, au-dessus de 1 en faveur de an implantable loop recorder.

Taux d’événements
Différence absolue
1,4 points

La différence absolue est dérivée des taux d’événements.

Également rapporté: No significant difference. Sudden cardiac death alone 1.7% vs 5.8% (HR 0.26, 95% CI 0.07-0.95). Below 70 years a 72% relative reduction in the primary endpoint, none above.

Publication originale
Sous-thème
Sudden death prevention
Schéma
Prospective, multicentre, open-label RCT, 1:1 (ICD vs implantable loop recorder), web-based randomisation stratified by site after core-lab LGE-CMR confirmation; recruitment mid-2015 to mid-2022, follow-up at least 3 years; Australia, UK and Europe
Pertinence
Important: l’un des piliers parmi d’autres.
Source
Selvanayagam JB, et al. JAMA. 2026; published online 28 August.doi 10.1001/jama.2026.17078

Discussion et critique

Scar on CMR does not by itself earn a defibrillator at an ejection fraction of 36-50%: the primary endpoint is neutral and the interval spans a halving and a 58% increase. The isolated reduction in sudden cardiac death and the benefit below 70 years are the interesting part and the fragile part: few events, a secondary endpoint and a subgroup. The comparator was an implantable loop recorder, so the control arm was monitored rather than treated, and recruitment ran from 2015 to 2022 while medical therapy changed underneath the trial.

Discuté dans des podcasts